Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
20.22
+0.22 (1.10%)
Mar 3, 2026, 4:00 PM EST - Market closed
Aktis Oncology Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Aktis Oncology stock has a target of 30, which predicts an increase of 48.37% from the current stock price of 20.22.
Analyst Consensus: Buy
Analyst Ratings
According to 1 stock analyst, the rating for Aktis Oncology is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $30 | Buy | Initiates | $30 | +48.37% | Feb 3, 2026 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $2 → $1 | Buy → Hold | Downgrades | $2 → $1 | -95.05% | Jan 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $6 → $3 | Buy | Maintains | $6 → $3 | -85.16% | Sep 7, 2023 |
| B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $9.25 → $1.75 | Strong Buy → Hold | Downgrades | $9.25 → $1.75 | -91.35% | Sep 7, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $6 | Buy | Maintains | $7 → $6 | -70.33% | May 9, 2023 |
Financial Forecast
Revenue This Year
7.79M
from 1.49M
Increased by 423.60%
Revenue Next Year
20.86M
from 7.79M
Increased by 167.90%
EPS This Year
n/a
from -62.46
EPS Next Year
n/a
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.5M | 52.5M | |
| Avg | 7.8M | 20.9M | |
| Low | 4.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 606.1% | 574.3% | |
| Avg | 423.6% | 167.9% | |
| Low | 229.5% | - |
EPS Forecast
| EPS |
|---|
| High |
| Avg |
| Low |
EPS Growth
| EPS Growth |
|---|
| High |
| Avg |
| Low |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.